Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.68 |
| ▸ | ACP1 | P24666 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 4/20 | 0.61 |
| ▸ | RAB9A | P51151 | 4/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | NPC1 | O15118 | 3/20 | 0.61 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.61 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL27891199 | 0.98 | ADORA2A (0.67) | ADORA2AACP1PKMRAB9ASMN1; SMN2 | |
| SCHEMBL12630120 | 0.88 | ACP1 (0.58) | ADORA2AACP1PKMRAB9ASMN1; SMN2 | |
| Chlorobenzene SCHEMBL9602640 | 0.87 | FFAR2 (0.63) | ADORA2ARAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL4112093 | 0.86 | ADORA2A (0.70) | ADORA2AACP1PKMRAB9ASMN1; SMN2 | |
| SCHEMBL10666660 | 0.84 | ACP1 (0.61) | ACP1PKMRAB9ASMN1; SMN2NPC1 | |
| Trifluoromethylbenzene SCHEMBL10350569 | 0.83 | MEN1 (0.65) | ADORA2APKMRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL2837501 | 0.83 | ACP1 (0.65) | ACP1PKMRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL2837504 | 0.83 | ACP1 (0.65) | ACP1PKMRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL1854243 | 0.83 | ADORA2A (0.71) | ADORA2ARAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL2605848 | 0.83 | SMN1; SMN2 (0.59) | ACP1PKMRAB9ASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021116260-A1 | QUINAZOLINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-06-17 | — | — | WO | claimed |
| WO-2020204548-A1 | NOVEL COMPOUND HAVING ANTICANCER ACTIVITY, AND METHOD FOR PRODUCING SAME | 재단법인 의약바이오컨버젼스연구단 | 2020-10-08 | — | — | WO | claimed |
| US-20100331346-A1 | BETA-AMINO ACID DERIVATIVES FOR TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-12-30 | — | — | US | claimed |
| EP-2091947-A2 | GLUCOKINASE ACTIVATORS | Takeda San Diego, Inc. (US) | 2009-08-26 | — | — | EP | claimed |
| EP-2049507-A2 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AND/OR AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF | Brystol-Myers Squibb Company (US) | 2009-04-22 | — | — | EP | claimed |
| EP-2049518-A2 | INDAZOLE AND ISOINDOLE DERIVATIVES AS GLUCOKINASE ACTIVATING AGENTS. | Takeda San Diego, Inc. (US) | 2009-04-22 | — | — | EP | claimed |
| EP-2024329-A2 | (2R)-2-[(4-SULFONYL)AMINOPHENYL]PROPANAMIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' pha.r.ma s.p.a. (IT) | 2009-02-18 | — | — | EP | claimed |
| EP-2001875-A2 | GLUCOKINASE ACTIVATORS | Takeda San Diego, Inc. (US) | 2008-12-17 | — | — | EP | claimed |
| WO-2008116107-A2 | PIPERAZINE DERIVATIVES AS GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. (US) | 2008-09-25 | — | — | WO | claimed |
| WO-2008079787-A2 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. (US) | 2008-07-03 | — | — | WO | claimed |
| WO-2008021926-A2 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AND/OR AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | claimed |
| WO-2007143434-A2 | INDAZOLE AND ISOINDOLE DERIVATIVES AS GLUCOKINASE ACTIVATING AGENTS | TAKEDA SAN DIEGO, INC. (US) | 2007-12-13 | — | — | WO | claimed |
| WO-2007135080-A2 | (2R)-2-[(4-SULFONYL)AMINOPHENYL]PROPANAMIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' PHA.R.MA. S.P.A. (IT) | 2007-11-29 | — | — | WO | claimed |
| WO-2007104034-A2 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. (US) | 2007-09-13 | — | — | WO | claimed |
| EP-1204649-A1 | ARYLMETHYL-CARBONYLAMINO-THIAZOLE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | Pharmacia Italia S.p.A. (IT) | 2002-05-15 | — | — | EP | claimed |
| WO-2001014353-A1 | ARYLMETHYL-CARBONYLAMINO-THIAZOLE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA ITALIA, S.P.A. (IT) | 2001-03-01 | — | — | WO | claimed |
| WO-2024126777-A1 | HETEROAROMATIC COMPOUNDS | ASTRAZENECA AB (SE) | 2024-06-20 | — | — | WO | disclosed |
| WO-2023220247-A1 | LRRK2 INHIBITORS | INTERLINE THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| CN-86108205-A | New thiazolium compounds and preparation method thereof and their pharmaceutical composition | — | 1987-06-17 | — | — | CN | disclosed |
| US-4293549-A | Quinolinyl guanidines having antiinflammatory, analgesic or antipyretic activity | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTION-SAKTIESELSKAB) (DK) | 1981-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331346-A1 | BETA-AMINO ACID DERIVATIVES FOR TREATMENT OF DIABETES | GPR119, GLS, GCKR | ADORA2A 1013/4885ACP1 755/4885PKM 1280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.